Athersys resolves stem cell patent dispute with Garnet Bio, settles for non-exclusive license; shares down 5% – Seeking Alpha
|
Athersys resolves stem cell patent dispute with Garnet Bio, settles for non-exclusive license; shares down 5%
Seeking Alpha Athersys (ATHX -4.6%) has agreed to settle its patent fight with Garnet BioTherapeutics related to stem cell technologies. Under the terms of the settlement, Garnet grants Athersys a global non-exclusive license license to Garnet patents related to the … |
